The Firm represented Boston-based MPM BioImpact in connection with the $20 million Series B-2 financing of Deka Biosciences, a Maryland-based biotech company.
Deka announced the successful completion of the round, led by MPM BioImpact, on Sept. 28. Detlev Biniszkiewicz, Ph.D., a managing director of MPM BioImpact, will join Deka’s board. Other participating investors included Leaps by Bayer, Lumira Ventures and O-Bio (Echo Investment Capital).
Founded in 2018, Deka Biosciences is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases.
Deka will use the proceeds to support the advancement of its pipeline and drug product manufacturing. With this financing, Deka will continue clinical trials for its new investigational new drug application to treat tumors, for which it has received a notice to proceed from the U.S. Food and Drug Administration (FDA).
Boston-based MPM BioImpact is a biotechnology investment firm founded in 1996 that invests in innovate biotechnology companies that are seeking to deliver transformative therapies to patients in the areas of highest unmet medical need.
Brown Rudnick attorneys Michael Cohen and Tyler Horowitz worked on the deal.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
